FOXP3 and neoplasm: With Treg cells expressing a high level of CTLA-4 (27), administration of an anti-CTLA-4 antibody has resulted in a major reduction in the frequency of intra-tumoral CTLA-4+FoxP3+ Treg cells which was dependent on Fcγ receptor-expressing cells in the tumor microenvironment (117–121).